The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...
Geography Should Not Be an “Oncologic Destiny” for Urothelial Cancer: Improving Access to Care by Removing Local, Regional, and International Barriers For more than a decade, advocates have urged ...
Health care access and disparities: A multidimensional and interdisciplinary approach to foster awareness in cancer clinical trials. Enrollment demographics vs GU onc, county, and state.
Reliable information and advocacy efforts empower kidney cancer patients to engage in research and treatment decisions. Pluvicto's FDA approval provides a new treatment for PSMA-positive metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results